Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus - Wikidata - awgldk - TriplyDB

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

http://www.wikidata.org/entity/Q36527897

about

Renal effects of dapagliflozin in patients with type 2 diabetes Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents Regulation of autophagy by TGF-β: emerging role in kidney fibrosis Autophagy in kidney health and disease.Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy.Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention De novo expression of sodium-glucose cotransporter SGLT2 in Bowman's capsule coincides with replacement of parietal epithelial cell layer with proximal tubule-like epithelium.Proximal tubule function and response to acidosis.Autophagy in diabetic nephropathy Empagliflozin in the treatment of type 2 diabetes: evidence to date Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL/6J model of diabetic nephropathy.The pathophysiology of hypertension in patients with obesity.Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.FSP-1 Impairs the Function of Endothelium Leading to Failure of Arteriovenous Grafts in Diabetic Mice Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats.SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.Antioxidant treatment attenuates lactate production in diabetic nephropathy.Tangshen formula attenuates diabetic renal injuries by upregulating autophagy via inhibition of PLZF expression.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update Transforming growth factor-β1 and diabetic nephropathy Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron.Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy?Sodium-glucose cotransport.Empagliflozin for the treatment of Type 2 diabetes.Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.Targeting cellular drivers and counter-regulators of hyperglycaemia- and transforming growth factor-β1-associated profibrotic responses in diabetic kidney disease.Novel effective drugs for diabetic kidney disease? or not?The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.

P2860

Q24564811-43DCBEFA-EC09-4B7C-A2D9-27EDCDF3A6F1 Q26777994-AE4310FB-A35A-44A0-A2C0-0AFFDEB96689 Q27010669-9B806C66-40B8-4CEC-9A85-A436054B69AA Q27023146-C1A3BB5C-F0A4-4FCA-9246-A4E6464B4C73 Q27687496-418DC4D6-7388-451B-9E61-5CFF1CC47F49 Q28085593-BC073920-2E17-419D-A8A3-08F471A899F2 Q30410876-E9CE7A77-D8BA-4567-A8C4-2BA15CAC0FDE Q30717371-59A18C73-7120-483D-AB83-B5BF1F547BAB Q33983846-C504CD05-CCA1-4A92-A9D5-AAEAAE677EDD Q34124765-CAD8C293-5929-4307-9214-E4324195384D Q34445143-168820B3-C80A-435A-9E7B-4238575F0DC6 Q34502358-E31B97F2-C544-43DF-98D7-21082DEFA720 Q34738579-A8963A98-2EBE-4B27-B29C-A57D0646A689 Q35021492-818A8518-4D3A-4594-8E4D-1F2CCE665A9C Q35137042-F802D81C-EB14-4C9A-A48E-4DB6A01F10E7 Q35194026-D7608F6E-B4C9-4C77-8E58-9B4B529F7F21 Q35392355-B44E9E22-80FE-4BD5-B272-011F5DBE60DC Q35603308-40E59A54-7DDA-4273-B12C-E125441D9D62 Q35749639-A33413A8-D583-42C8-BAF3-96D5E59952BC Q36004330-70CCBEDE-AB44-49ED-8672-A4E2B800D50B Q36237217-46A87AFD-7935-43B5-8530-A456E01089C4 Q36245001-52AC9721-56CB-4400-91AC-92F8FE10F44C Q36275517-6902318F-D3AD-4132-A3DA-E4A136CB271E Q36435496-1A06AFE7-8A1D-4124-A500-714087D6291B Q36810701-741ECE4F-9E51-486D-8DA0-D56A9BC5E072 Q36937697-00EBEC44-4740-4572-BB41-974FDD70AA2F Q37072443-AB344618-6B2A-4BC9-BA2F-CE942E9DFBC5 Q37219076-C57479F3-136A-4969-BA9B-1723FE7C86DB Q37524302-51725521-F472-4FC1-8581-38FE9BE7C0D0 Q37559899-05F3E840-9AFD-47C8-9334-16558794D10E Q37575455-F514749A-50B1-4C29-A0ED-6263D3457246 Q37575461-7C9056E6-F22D-44EF-A0A9-9C46924364D6 Q37661798-A7194C19-CE5F-4903-BC87-E92323BE2D3E Q37686261-C1CCD521-630D-42C3-9D50-CEE51DFE10F8 Q37718851-6BAF3AFB-91D5-4647-A232-475E8A0009B6 Q38203327-2C9D30DB-5F74-4D31-898C-37082256DCAC Q38236209-F0DDE805-31FD-4A32-B2FA-3047136428CD Q38236212-B7C557DB-C0F0-4DA2-BA13-6BE74B92AFDC Q38265818-D4DCCB12-696A-4905-9B2F-0E7071E3538A Q38306298-52A4CEE5-2979-4654-AA36-682009B1ED9B

P2860

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus

http://www.wikidata.org/entity/Q36527897

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Knockout of Na-glucose transpo ...... or injury in diabetes mellitus

@ast

Knockout of Na-glucose transpo ...... or injury in diabetes mellitus

@en

type

label

Knockout of Na-glucose transpo ...... or injury in diabetes mellitus

@ast

Knockout of Na-glucose transpo ...... or injury in diabetes mellitus

@en

prefLabel

Knockout of Na-glucose transpo ...... or injury in diabetes mellitus

@ast

Knockout of Na-glucose transpo ...... or injury in diabetes mellitus

@en

P1433

Q36527897-86EEF829-22D2-4662-A5B2-6D035981AF5F

P1476

Q36527897-66B8033F-323E-4445-8D1C-9C72272E6C8A

P2093

Q36527897-059634F9-BA22-4D26-BC2B-04CD6088075B

Q36527897-15024D8B-B492-4C38-9D33-D8B9A54CFC1D

Q36527897-24BA32CC-CAA5-46AA-BCCC-41C1D5483C26

Q36527897-3497B3CE-1329-41DA-8892-1055631CD107

Q36527897-4FAB6C7E-023F-4AE6-A966-15BDE423B5FE

Q36527897-6A353774-B357-43C5-9F69-B37850149551

Q36527897-95D18965-3B0C-4E94-A482-8EBB4FDA25D7

Q36527897-F38B0064-EA69-4AD9-A9D7-8EC6A7DEEEA0

P2860

Q36527897-107187C1-A685-4998-9456-68F7BEDC7E33

Q36527897-12C29D11-ED17-4637-B7B4-B64D674E959E

Q36527897-13D38D5D-659D-4EC4-987F-7FAB35A4AFB0

Q36527897-308916B4-A1D2-4834-9290-DBB4B71AA413

Q36527897-34BCC036-AAE7-4205-81C5-D3ABB4E2E0A2

Q36527897-38FD9B26-C05B-4FA3-BD0D-1ABC0B85E460

Q36527897-399F99B5-F342-4AB7-B62D-A05E93B5959D

Q36527897-463B46CD-301C-4AF3-BA45-0EA58E76F07D

Q36527897-52CDACF0-F2BF-448E-BE68-5E6794FAFD55

Q36527897-54785340-86FE-44A6-8874-2497D55E41BD

P304

Q36527897-B1258D9C-E390-4964-9FAA-D134215C706C

P31

Q36527897-991E3EEC-6684-4832-AA19-EA304FFFBB77

P356

Q36527897-62970C01-8455-4A3A-9D4C-1BE1BFDDF111

P433

Q36527897-402A9E00-E2E7-4B8A-89BF-D52367B35B49

P478

Q36527897-F9F48DFF-14D8-4A37-B19D-9DD57E79DC07

P50

Q36527897-8F8F4987-6F69-41C7-B9A8-281C11343CC4

Q36527897-C1D287E5-E056-4B3E-A55F-65DACC06B25B

P577

Q36527897-2886A936-AD65-4209-8E7D-A63E97D24DC5

P5875

Q36527897-330944F9-8C4A-4F33-AD7C-5DFF24DD766F

P698

Q36527897-B4567496-47CF-40EF-8A00-826057BCFB8A

P921

Q36527897-91D46520-31C3-46F0-99F6-E865ECA079A1

P932

Q36527897-A3BE5D71-F600-4F5E-A2FB-AFEF98369045

P356

AJPRENAL.00409.2012

P1433

American Journal of Physiology - Renal Physiology

P1476

Knockout of Na-glucose transpo ...... or injury in diabetes mellitus

@en

P2093

Hermann Koepsell

http://www.w3.org/2001/XMLSchema#string

Joseph Satriano

http://www.w3.org/2001/XMLSchema#string

Kenneth A Platt

http://www.w3.org/2001/XMLSchema#string

Kumar Sharma

http://www.w3.org/2001/XMLSchema#string

Maria Gerasimova

http://www.w3.org/2001/XMLSchema#string

Michael Rose

http://www.w3.org/2001/XMLSchema#string

Robyn Cunard

http://www.w3.org/2001/XMLSchema#string

Scott C Thomson

http://www.w3.org/2001/XMLSchema#string

P2860

A new mathematical model for relative quantification in real-time RT-PCR

STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells

Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes

Cloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney

p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death

Autophagy and the integrated stress response

Mouse models of diabetic nephropathy.

Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes.

Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla.

SGLT2 mediates glucose reabsorption in the early proximal tubule.

P304

F156-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00409.2012

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

304

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233418887

http://www.w3.org/2001/XMLSchema#string

P698

23152292

http://www.w3.org/2001/XMLSchema#string

P921

P932

3543626

http://www.w3.org/2001/XMLSchema#string